Antifungal therapy – Page 16

Extensive and recurrent infection caused by Medicopsis romeroi in two immunocompromised patients

mycolabadmin

This case report describes two patients with weakened immune systems who developed serious fungal skin infections caused by a rare mold called Medicopsis romeroi. Both patients underwent multiple surgeries and required extended antifungal medication treatment lasting months to years. The study demonstrates that successful treatment requires a combination approach including surgical removal of infected tissue, adjustment of immunosuppressive medications, and prolonged antifungal therapy.

Invasive Fusarium rhinosinusitis in COVID-19 patients: report of three cases with successful management

mycolabadmin

This study reports three cases of rare fungal sinus infections caused by Fusarium species that developed in COVID-19 patients. All three patients were successfully treated with a combination of surgical removal of infected tissue and antifungal medications. The cases highlight how COVID-19 and the use of steroids to treat it can increase the risk of serious fungal infections, emphasizing the importance of early detection and prompt treatment.

Invasive fungal infections caused by rare yeast-like fungi in adult patients: results of a prospective study

mycolabadmin

This study examined rare fungal infections in 30 critically ill adult patients over 18 years, finding that infections caused by uncommon yeasts like Trichosporon and Rhodotorula affected mainly long-term ICU patients with central lines. Despite treatment with antifungal medications, about 37% of patients died, highlighting the serious nature of these infections. The research emphasizes the importance of quickly identifying the specific fungus causing infection and using appropriate medications, along with removing infected catheters, to improve patient survival.

A case of Blastomyces helicus pneumonia in a dog from a non-endemic region: diagnostic challenges and successful treatment outcome

mycolabadmin

A dog developed severe pneumonia from an emerging fungal infection called Blastomyces helicus after traveling to Utah and Idaho. Initial blood tests incorrectly suggested a different fungus, but laboratory culture and genetic testing identified the true culprit. The dog was successfully treated with an antifungal medication called itraconazole and made a complete recovery with careful monitoring over 6 months.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after receiving an artificial valve replacement. The initial antibiotic (itraconazole) did not work because the fungus became resistant, likely by forming a protective biofilm. After identifying the resistant fungus through specialized testing, doctors switched to a different medication called caspofungin. The patient fully recovered with this new treatment and remained healthy during follow-up, showing that combination of precise identification and targeted treatment can overcome antibiotic resistance.

A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant Candida auris infection

mycolabadmin

Researchers tested a new drug called APC6 that works by trapping zinc, which fungi need to survive. In mouse studies of a dangerous resistant fungus called Candida auris, APC6 saved all treated mice while most untreated mice died. The drug also reduced fungal infections in organs without causing serious side effects, suggesting it could become a new treatment option for serious fungal infections resistant to current medicines.

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous yeast that causes a serious lung infection called empyema, where pus collects around the lungs. This infection is particularly difficult to treat because the yeast is resistant to common antifungal drugs like fluconazole and can form protective biofilms. This systematic review identified only ten cases of this rare infection in the medical literature, showing how uncommon but serious it is, and found that patients need aggressive treatment with multiple antifungal medications combined with surgical drainage to survive.

Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy against Fonsecaea monophora in vitro

mycolabadmin

Chromoblastomycosis is a stubborn skin fungal infection that is difficult to treat with current medications and often comes back after treatment. Researchers tested a new treatment using a special light-activated compound called COP1T-HA combined with blue light, which successfully killed the fungus in laboratory tests. The treatment worked quickly and at low doses, showing promise as a potential new therapy for this challenging infection.

Superficial Fungal Infections in Children—What Do We Know?

mycolabadmin

Fungal infections of the skin, hair, and nails are increasingly common in children worldwide, especially in warm, humid climates and in crowded living conditions. These infections are caused by germs that live on the skin and can spread through contact with infected people or animals. Children are particularly vulnerable due to their developing immune systems, but most infections are treatable with topical creams or oral medications, with terbinafine being the most effective option currently available.

Invasive Saprochaete capitata Infection in an Immunocompromised Patient With Acute Myeloid Leukemia: A Case Report

mycolabadmin

A 46-year-old man with blood cancer developed a serious fungal infection caused by Saprochaete capitata during chemotherapy. This rare but dangerous fungus was found in his blood and lungs, causing fever and breathing problems. The patient was successfully treated with a combination of two antifungal medications and fully recovered, though this infection typically has a high death rate.

Research Topic: Antifungal therapy